Can medical management with teriparatide improve spinal surgery outcomes in patients with spinal osteoporosis/osteopenia?

Publication date: March 2018

Source: Seminars in Spine Surgery, Volume 30, Issue 1

Author(s): Muhammad Shakib Akhter, Hussein Ali El-Khechen, Rakesh Patel, Ilyas S. Aleem

Abstract

Osteopenia and osteoporosis have become increasingly common in the elderly population, as has the concern from treating spinal surgeons. Many adverse surgical outcomes have been associated with poor bone quality, including decreased fusion rates, hardware complications, and osteoporotic fractures. Teriparatide, a recombinant form of parathyroid hormone, has been used as a major pharmaceutical intervention in osteoporosis treatment. This article provides an overview of the mechanism of teriparatide followed by a detailed review of the literature concerning outcomes of medical management with teriparatide in both animal models and humans with osteoporosis/osteopenia. Improved fusion rates and duration, as well as reduced osteoporosis-related complications are evident upon reviewing clinical and radiographic outcomes of teriparatide therapy in spinal surgery patients.

https://ift.tt/2NOw1sV